← Evidence library

BIB_405

i31-GEP-for-SLNB prospective DECIDE trial (Guenther 2025) — evidence-check of the GEP-to-forego-SLNB use case in a cohort whose MEDIAN Breslow is 0.8 mm and 40.7% T1b (this patient's exact profile). Verdict: methodologically the strongest prospective i31-GEP-SLNB data to date (0/35 of <5%-risk patients had a positive node; 18.5% fewer SLNBs) BUT entirely Castle-Biosciences-funded, US-only, no independent data release, and NOT adopted by NHS/NICE/BAD/ESMO. Strengthens — does not overturn — the brief's existing "decline GEP at IB; UK pathway + AMBLor govern" position (TASK15 §15.6, BIB153, BIB…

Evidence grade

B

Tier

2 (World J Sur

Cited by tasks

4, 15, 24

Identifiers

PMC11697456 · DOI:10.1186/s12957-024-03640-x · PMID:39754143

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_405/findings.md (research corpus). This page is a short context summary — not individualised medical advice.